Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Hearing Loss is Rare in Tepezza Treatment for TED
A recent study, led by Dr. Raymond Douglas, MD, PhD, revealed that long-term hearing loss is a rare occurrence in individuals with normal audiometry at baseline following treatment with Tepezza [teprotumumab]. Published in the current issue of the prestigious journal…
T. Boone Pickens Foundation’s $20M Donation
Founded by the late Texan visionary energy magnate and philanthropist, the T. Boone Pickens Foundation is donating a substantial sum of $20 million to the Wilmer Eye Institute, part of Johns Hopkins Medicine. This significant donation, initially announced in 2013,…
FTC Clears Amgen’s Acquisition of Horizon Therapeutics
Amgen is set to proceed with its acquisition of Horizon Therapeutics after reaching an agreement with the Federal Trade Commission (FTC). This agreement clears the way for Amgen to complete its acquisition of Horizon Therapeutics, a deal valued at $27.8…
Allotex Receives Funding for Allogeneic Presbyopia Inlays
Allotex and SpA have announced the successful completion of the first close of their $30 million Series B financing. The funds raised will be utilized to further develop their technology aimed at treating refractive errors. The decision to invest in…
New Study Reveals Insights into Glaucoma in Africans
A team of investigators unveiled previously unknown inherited genetic variants associated with primary open-angle glaucoma (POAG), the most prevalent form of the disease. The study, based on the analysis of 11,275 individuals of African descent, sheds light on the genetic…
Aviceda Launches Phase 2 Clinical Trial for AVD-104
Aviceda Therapeutics announced a significant milestone in the development of its lead ophthalmic candidate, AVD-104, with the enrollment of the first patient in the GLYCO phase 2 US clinical trial. The trial aims to evaluate the efficacy and safety of…
Study Unveils Pupil Response Discrepancy in Depression Patients
In a recent study conducted by scientists from the Max Planck Institute of Psychiatry, researchers delved into the realm of pupillary reactions to uncover valuable insights into the physiological mechanisms underlying depression. The study, led by research group leader Victor…
FDA Approves ZEISS’ VISUMAX® 800 for Nearsightedness
The FDA has approved the VISUMAX® 800 equipped with SMILE® pro software from ZEISS. This state-of-the-art femtosecond laser technology is designed for the surgical treatment of nearsightedness, with or without astigmatism. The VISUMAX® 800 enters the U.S. market at a…
Ocuphire Pharma Gets FDA Nod for Dim Light Visual Acuity Trial
In a recent announcement, Ocuphire Pharma disclosed that it has secured approval from the U.S. Food and Drug Administration (FDA) under a special protocol assessment (SPA) for the clinical trial protocol and planned statistical analysis of its LYNX-2 phase 3…
Promising Treatment for Endothelial Disease
In a groundbreaking study published in The American Journal of Pathology, researchers at Mass Eye and Ear of the Harvard Medical School Department of Ophthalmology have unveiled a novel therapeutic approach using the neuropeptide α-melanocyte–stimulating hormone (α-MSH) to promote corneal…